Advanced Search
YE Qing, WANG SHuo, LIU Li-jiang, et al, . The study of specificity and stability of an anti-CD71 mouse/human chimeric antibody(Dd2C)-secreted transfectomas keeping in liquid nitrigen[J]. Cancer Research on Prevention and Treatment, 2003, 30(02): 95-97. DOI: 10.3971/j.issn.1000-8578.3145
Citation: YE Qing, WANG SHuo, LIU Li-jiang, et al, . The study of specificity and stability of an anti-CD71 mouse/human chimeric antibody(Dd2C)-secreted transfectomas keeping in liquid nitrigen[J]. Cancer Research on Prevention and Treatment, 2003, 30(02): 95-97. DOI: 10.3971/j.issn.1000-8578.3145

The study of specificity and stability of an anti-CD71 mouse/human chimeric antibody(Dd2C)-secreted transfectomas keeping in liquid nitrigen

More Information
  • Corresponding author:

    YE Qing

  • Received Date: July 29, 2002
  • Revised Date: October 20, 2002
  • Objective To study the specificity and stability of an anti CD71 mouse/human chimeric antibody (D2C) secreted transfectomas keeping in liquid nitrogen for tow years. Methods Analysis of the chimeric Ab production in culture supernatant was made by the standard concentration curve method with ELISA. The antibody (D2C) was purified by DEAE Sephredax A50 ion exchange chromatography from ascites and was confirmed by SDS PAGE . Results The production of the chimeric Ab(D2C) in the culture supernatant wa...
  • Related Articles

    [1]HUANG Qing, XUE Chang, HU Sheng. Development on Cancer Therapeutic Drugs Approved by FDA in 2023[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 542-545. DOI: 10.3971/j.issn.1000-8578.2024.24.0040
    [2]ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257
    [3]CHEN Jiachen, WU Tingyu, XIA Weiliang. Relationship of EGFR-TKI Targeted Therapy and Pyroptosis in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1185-1190. DOI: 10.3971/j.issn.1000-8578.2023.23.0310
    [4]JI Xiaojun, ZHAO Tingli, MIAO Lei, SI Yaxuan, WU Jian, XU Dan. Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 413-421. DOI: 10.3971/j.issn.1000-8578.2023.22.1056
    [5]LIU Shanting, QIN Jiali, FAN Jie. Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 6-11. DOI: 10.3971/j.issn.1000-8578.2023.22.0869
    [6]YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
    [7]ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(6): 505-513. DOI: 10.3971/j.issn.1000-8578.2022.21.1514
    [8]YANG Changliang, ZHANG Shuang, LIU Jingjing, LI Shuang, CHENG Ying. New Immune Checkpoint: Advances in Immunotherapy for Malignant Tumors[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 1027-1035. DOI: 10.3971/j.issn.1000-8578.2018.18.0545
    [9]CHEN Rui, ZHAO Da, WANG Li'na. Mechanism and Strategies on Drug Resistance of Non-small Cell Lung Cancer to EGFR-TKI[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 225-230. DOI: 10.3971/j.issn.1000-8578.2017.03.014
    [10]FENG Chengjun, LIU Xiaoke, LI Xiaoyu, WANG Yongsheng. Progress of Zoledronic Acid Combined with Targeted or Immunomodulatory Drugs in Antitumor Research[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 843-847. DOI: 10.3971/j.issn.1000-8578.2015.08.020

Catalog

    et al

    1. On this Site
    2. On Google Scholar
    3. On PubMed
    Article views (2778) PDF downloads (682) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return